Grow Your Pharma Business Digitally

Find Suppliers : API/FDF
- Search Our Integrated Database
Services
Excipients
Drugs in Dev.
News
Blog
Market Place
Login

List of clinical trials for Undisclosed highest development status

Undisclosed

DRL offers a portfolio of products & services, including APIs, CMO services, generics, biosimilars & differentiated formulations.

Contact Supplier

Valsynthese, part of the SSE Group, is a CDMO focused on highly energetic and highly hazardous chemistry.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

With Fermion, start the journey of your innovative API.

Contact Supplier

Bloomage is a one-stop source for CEP Sodium Hyaluronate and Hyaluronic Acid// FDA-inspected & GMP-certified.

Contact Supplier

xyz-pharma-m-2024-10-07

Contact Supplier

Filters

FILTER :

filter Interventions

All

Insulin

Leptin

filter Therapeutic Area

All

Endocrinology

Nutrition and Weight Loss

filter Condition

All

Type 2 diabetes mellitus

Weight loss

filter Study Phase

All

Undisclosed

filter Location

All

Blank

Oramed Pharmaceuticals

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

U.s.a

Digital Content

Oral Combination Therapy for the Management of T2DM, by Combining the Advantages of ORMD-0801 and ORMD-0901

Highest Development Status: Undisclosed

Therapeutic Area: Endocrinology

Interventions: Exenatide,Insulin

Product Type: Large molecule

Sponsor: Oramed Inc

Receptors: Insulin receptor agonist||Gluc...

Trial ID: NA

Location: NA

Condition: Type 2 diabetes mellitus

Product Status: Approved

Dosage Form: Oral

Collaborator: NA

Recruitment Status: NA

Date Of Registration: NA

Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.

01

Oramed Pharmaceuticals

U.S.A

Antibody Engineering

Not Confirmed

Oramed Pharmaceuticals

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Highest Development Status: Undisclosed

Therapeutic Area: Endocrinology

Interventions: Exenatide,Insulin

Location: NA

Sponsor: Oramed Inc

Trial ID: NA

Oral Combination Therapy for the Management of T2DM, by Combining the Advantages of ORMD-0801 and ORMD-0901

Product Description: ORMD-0801 (Oral Insulin) capsule and ORMD-0901 (Exenatide), a GLP-1 analog are pursuing an oral combination therapy for the management of T2DM without an increased risk for hypoglycemia.

Product Status: Approved

Dosage Form: Oral

Collaborator: NA

Recruitment Status: NA

Date Of Registration: NA

Condition: Type 2 diabetes mellitus

Product Type: Large molecule

Receptors: Insulin receptor agonist||Glucagon-lik...

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

Oramed Pharmaceuticals

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Post an Enquiry

Post an Enquiry

U.s.a

Digital Content

Evaluation of Oral Leptin for Glucagon Reduction in Type 1 diabetes, with a Long-term Goal of Addressing Weight Loss

Highest Development Status: Undisclosed

Therapeutic Area: Nutrition and Weight Loss

Interventions: Leptin

Product Type: Large molecule

Sponsor: Oramed Inc

Receptors: Leptin receptor agonist

Trial ID: NA

Location: NA

Condition: Weight loss

Product Status: Undisclosed

Dosage Form: Capsule

Collaborator: NA

Recruitment Status: NA

Date Of Registration: NA

Product Description: Leptin is a hormone predominantly made by adipose cells and enterocytes in the small intestine that helps to regulate energy balance by inhibiting hunger, which in turn diminishes fat storage in adipocytes.

02

Oramed Pharmaceuticals

U.S.A

Antibody Engineering

Not Confirmed

Oramed Pharmaceuticals

U.S.A

Antibody Engineering

Not Confirmed

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

Highest Development Status: Undisclosed

Therapeutic Area: Nutrition and Weight Loss

Interventions: Leptin

Location: NA

Sponsor: Oramed Inc

Trial ID: NA

Evaluation of Oral Leptin for Glucagon Reduction in Type 1 diabetes, with a Long-term Goal of Addressing Weight Loss

Product Description: Leptin is a hormone predominantly made by adipose cells and enterocytes in the small intestine that helps to regulate energy balance by inhibiting hunger, which in turn diminishes fat storage in adipocytes.

Product Status: Undisclosed

Dosage Form: Capsule

Collaborator: NA

Recruitment Status: NA

Date Of Registration: NA

Condition: Weight loss

Product Type: Large molecule

Receptors: Leptin receptor agonist

Portfolio PDF

Product Web Link

Digital Content

Corporate PDF

First

Last